ImmunoCellular Therapeutics Ltd : ImmunoCellular Therapeutics' ICT-107 featured on CNN's Sanjay Gupta MD
08/13/2012| 12:40pm US/Eastern
ImmunoCellular Therapeutics (NYSE MKT: IMUC) a clinical stage
biotechnology company that is focused on developing new immune-based
products to treat cancer, announced today that it was featured on CNN's
Sanjay Gupta MD last weekend. The show profiled IMUC's dendritic
cell-based vaccine, ICT-07, which is currently undergoing a Phase IIb
clinical trial treating newly diagnosed patients with glioblastoma
multiforme, an aggressive, terminal form of brain cancer.
Dr. Sanjay Gupta is the multiple Emmy®-award winning chief medical
correspondent for CNN. Gupta, a practicing neurosurgeon, plays an
integral role in CNN's reporting on health and medical news for Starting
Point with Soledad O'Brien, Anderson Cooper 360°, CNN documentaries, and
anchors the weekend medical affairs program Sanjay Gupta MD. Gupta also
contributes to CNN.com and CNNHealth.com.
ImmunoCellular's Phase IIb trial of ICT-107 is a double-blind,
placebo-controlled, 2:1 randomized study designed to evaluate the safety
and efficacy of ICT-107. The study is enrolling patients at medical
institutions in collaboration with leading experts and opinion leaders
A transcript of the CNN show can be found at: http://edition.cnn.com/TRANSCRIPTS/1208/11/hcsg.01.html
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics (IMUC)
is a Los Angeles-based clinical-stage company that is developing
immune-based therapies for the treatment of brain and other cancers. The
Company is currently conducting a Phase IIb trial of its lead product
candidate, ICT-107, a dendritic cell-based vaccine targeting multiple
tumor associated antigens for newly diagnosed glioblastoma. To learn
more about IMUC, please visit www.imuc.com.
This press release contains certain forward-looking statements that
are subject to a number of risks and uncertainties, including the risk
that the prior safety and efficacy results for ICT-107 will not be
confirmed in current or any subsequent trials of that product candidate
in statistically significant larger patient populations. Additional
risks and uncertainties are described in IMUC's most recently filed SEC
documents, such as its most recent annual report on Form 10-K, all
quarterly reports on Form 10-Q and any current reports on Form 8-K. IMUC
undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
For ImmunoCellular Therapeutics, Ltd.
© Business Wire 2012